Stay updated on Daratumumab in High-Risk MGUS & Low-Risk Smoldering Clinical Trial
Sign up to get notified when there's something new on the Daratumumab in High-Risk MGUS & Low-Risk Smoldering Clinical Trial page.
Latest updates to the Daratumumab in High-Risk MGUS & Low-Risk Smoldering Clinical Trial page
- Check7 days agoChange DetectedThe website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant change in its functionality.SummaryDifference0.2%
- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.1%
- Check43 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information for individuals who can answer questions about joining the study, along with the location details.SummaryDifference2%
- Check57 days agoChange DetectedSeveral key resources related to multiple myeloma and monoclonal gammopathy of undetermined significance have been removed, including links to MedlinePlus and Rare Diseases, which may impact access to important information on these conditions.SummaryDifference4%
- Check64 days agoChange DetectedNew resources related to multiple myeloma and monoclonal gammopathy have been added, including links to MedlinePlus and Rare Diseases information.SummaryDifference0.5%
- Check72 days agoChange DetectedThe website has been updated to version v2.12.2, adding new features for downloading data in various formats and allowing users to select specific fields for export.SummaryDifference4%
Stay in the know with updates to Daratumumab in High-Risk MGUS & Low-Risk Smoldering Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab in High-Risk MGUS & Low-Risk Smoldering Clinical Trial page.